DOI:
10.1055/s-00035024
Thrombosis and Haemostasis
LinksClose Window
References
Hohnloser SH, Cappato R, Ezekowitz MD. et al. X-VeRT Steering Committee and Investigators.
Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial.
Europace 2016;
18 (02) 184-190
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.